Skip to main content

ADVERTISEMENT

Javier Pinilla-Ibarz, MD, PhD

Javier Pinilla-Ibarz, MD, PhD
Conference Coverage
01/29/2024
During the Lymphoma, Leukemia & Myeloma Congress, Javier Pinilla-Ibarz, MD, PhD, debated that BTK inhibitors are the preferred treatment regimen for patients with CLL.
During the Lymphoma, Leukemia & Myeloma Congress, Javier Pinilla-Ibarz, MD, PhD, debated that BTK inhibitors are the preferred treatment regimen for patients with CLL.
During the Lymphoma, Leukemia &...
01/29/2024
Oncology